Glucocorticoid induced osteoporosis

International Journal of Pharmaceutical Sciences Review and Research

Volumn 5, Issue 3, 2010, Pages 124-131

  Chiluka, Vijaya Laxmi ^a   Banji, David ^a   Banji, Otilia J F ^a   Sollu, Murali ^a   Pandra, Sonia Bindu ^a  

^a Nalanda College of Pharmacy   (India)

Author keywords

Bisphosphonates; Diagnosis; Glucocorticoids; Osteoporosis

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; ANABOLIC AGENT; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; COLLAGEN PYRIDINIUM; ETIDRONIC ACID; FLUORIDE; GLUCOCORTICOID; HERBACEOUS AGENT; HYDROXYPROLINE; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; PROCOLLAGEN; PROCOLLAGEN TYPE 1; PYRIDINIUM DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TIBOLONE; UNCLASSIFIED DRUG; VITAMIN D;

ABSORPTIOMETRY; ARTHRALGIA; BONE DENSITY; BONE MINERALIZATION; BONE REMODELING; BREAST TENDERNESS; COMMIPHORA WIGHTII; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIZZINESS; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DUAL ENERGY X RAY ABSORPTIOMETRY; DUAL PHOTON ABSORPTIOMETRY; ECHOGRAPHY; ESOPHAGUS DISEASE; ESTROGEN THERAPY; GASTROINTESTINAL IRRITATION; HEADACHE; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; LEG CRAMP; LOW DRUG DOSE; MEDICINAL PLANT; MYALGIA; NAUSEA; NEURASTHENIA; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY; PHOTON ABSORPTIOMETRY; PRIMARY OSTEOPOROSIS; QUANTITATIVE COMPUTED TOMOGRAPHY; QUANTITATIVE ULTRASONOGRAPHY; RADIOGRAPHIC ABSORPTIOMETRY; REVIEW; SECONDARY OSTEOPOROSIS; SIDA CORDIFOLIA; SIDE EFFECT; SINGLE PHOTON ABSORPTIOMETRY; TERMINALIA ARJUNA; THROMBOEMBOLISM; VANDA ROXBURGHII; WITHANIA SOMNIFERA;

EID: 79952047641     PISSN: None     EISSN: 0976044X     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Sampson WH, Alcohol and other factors affecting osteoporosis risk in women, Alcohol Research & Health, 2002, 26, 292-298.
2. Barnett E, Nordin. BEC, Radiological Assessment of Bone Density, the British Journal of Radiology, 1961, 34, 683-692.
3. Jagelaviciene E, Kubilius R, The relationship between general osteoporosis of the organism and periodontal diseases, Medicina (Kaunas), 2006, 42, 613-618.
4. Cheung RKH, Leung KK, Lee KC, Chow TC, Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate, Hong Kong Medical Journal, 13(6), 2007, 485-489.
5. Hurson CJ, Butler JS, Keating DT, Murray DW, Sadlier DM, Byrne JM, Doran PP, Gene expression analysis in human osteoblasts exposed to dexamethasone identifies altered developmental pathways as putative drivers of osteoporosis, BMC Musculoskeletal Disorders, 2007, 8, 1-12.
6. Annapoorna N, Rao GV, Reddy NS, Rambabu P, Samabasiva Rao KRS, An Increased Risk of Osteoporosis during Acquired Immunodeficiency Syndrome, International Journal of Medical Sciences, 2004, 1, 152-164.
7. Adler RA, Hochber MC, Suggested Guidelines for Evaluation and Treatment of Glucocorticoid- Induced Osteoporosis for the Department of Veterans Affairs, Archives of Internal Medicine, 2003, 163, 2619-2624.
8. Khan AA, Hanley DA, Bilezikian JP, Binkley N, Brown JP, Hodsman AB, Josse RG, Kendler DL, Lewiecki EM, Miller PD, Olszynski WP, Petak SM, Syed ZA, Theriault D, Watts NB, Standards for Performing DXA in Individuals With Secondary Causes of Osteoporosis, Journal of Clinical Densitometry, 2006, 9, 47-57.
9. Saklatvala J, Glucocorticoids: do we know how they work?, Arthritis Research, 2002, 4, 146-150.
10. Riley K, Martin J, Wazny LD, Impact of pharmacist intervention on osteoporosis treatment after fragility fracture, Committee to Protect Journalists, 2005, 138, 37-43.
11. McDonough AK, Curtis JR, Saag KG, The epidemiology of glucocorticoid-associated adverse events, Current Opinion in Rheumatology, 2008, 20, 131-137.
12. Struijs A, Smals A, De witte SA, Hackeng WHL, Mulder H. acute effects of etidronate on glucocorticoid induced degradation, rheumatology, 2000;39:523-29.
13. Lei SF, Chen Y, Xiong DH, Li LM, Deng HW, Ethnic difference in osteoporosis-related phenotypes and its potential underlying genetic determination, Journal of Musculoskeletal Neuronal Interactions, 2006, 6, 36-46.
14. Geusens P, Dinant G, Integrating a Gender Dimension into Osteoporosis and Fracture Risk Research, Gender Medicine, 2007, 4, 147-161.
15. Freeman J, Turner L, Osteoporosis: It's More Than Calcium, Californian Journal of Health Promotion 2004, 2, 12-29.
16. Atrushkevich VG, Dmitrieva LA, Pikhlak UA, State of periodontal tissues in patients with systemic osteoporosis on the background of rheumatoid arthritis, Gerontologija, 2006, 7, 143-146.
17. Kansra U, Osteoporosis - Medical Management, Journal, Indian Academy of Clinical Medicine, 2002, 3, 128-140.
18. Fitzpatrick LA, Secondary Causes of Osteoporosis, Mayo clinic proceedings, 2002, 77, 453-468.
19. Mueller M, Russell RGG, Osteoporosis: pathogenesis and clinical intervention, Biochemical Society Transactions, 2003, 31, 462-464.
20. Yao W, Cheng Z, Pham A, Busse C, Zimmermann EA, Ritchie RO, Lane NE, Glucocorticoid-Induced Bone Loss in Mice Can Be Reversed by the Actions of Parathyroid Hormone and Risedronate on Different Pathways for Bone Formation and Mineralization, Arthritis & Rheumatism, 2008, 58, 3485-3497.
21. Heaney RP, Calcium, Dairy Products and Osteoporosis, Journal of the American College of Nutrition, 2000, 19, 2, 83-99.
22. Akesson K, New approaches to pharmacological treatment of osteoporosis, Bulletin of the World Health Organization, 2003, 81, 657-663.
23. Hartman C, Hochberg Z, Shamir R, Osteoporosis in Pediatrics, Journal of Indian Medical Association, 2003, 5, 509-515.
24. Yamada S, Takagi H, Tsuchiya H, Nakajima T, Ochiai H, Ichimura A, Iwata H, Toriyama T, Comparitive studies on risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients, Yakugaku Zasshi, 2007, 127, 1491-1496.
25. Uchida K, NakajimaH, Miyazaki T, Yayama T, Kawahara H, Kobayashi S, Tsuchida T, Okazawa H, Fujibayashi Y, Baba H, Effects of Alendronate on Bone Metabolism in Glucocorticoid-Induced Osteoporosis Measured by 18F-Fluoride PET: A Prospective Study, Journal of Nuclear Medicine, 2009, 50, 1808-1814.
26. Migliaccio S, Brama M, Malavolta N, Management of glucocorticoids-induced osteoporosis: role of teriparatide, Therapeutics and Clinical Risk Management, 2009, 5, 305-310.
27. Libanati CR, Baylink DJ, Prevention and Treatment of Glucocorticoid-Induced Osteoporosis A Pathogenetic Perspective, Chest, 1992, 102, 1426-1435.
28. Xie F, Wu CF, Lai WP Yang XJ, Cheung PY, Yao XS, Leung PC, Wong MS, The osteoprotective effect of Herba epimedii (HEP) extract in vivo and in vitro, the Journal and Oxford University Press, 2005, 1-9.
29. Lacativa PGS, De Farias MLF, Office Practice of Osteoporosis Evaluation, Arquivos Brasileiros de Endocrinologia & Metabologia, 2006, 50, 674-684.
30. Thomakos N, Liakakos T, Diagnostic methods in osteoporosis, Archives of Hellenic Medicine, 2000, 17, 146-151.
31. Maghraoui AE, Habbassi A, Lahsen MG, Mounach A, Nouijai A, Bezza A, Validation and comparative evaluation of four osteoporosis risk indexes in Moroccan menopausal women, Arch Osteoporosis, 2006, 1, 1-6.
32. Munns CJF, Cowell CT, Prevention and treatment of osteoporosis in chronically ill children, Journal of Musculoskeletal Neuronal Interactions, 2005; 5, 262-272.
33. Yeap SS, Hosking DJ, Management of corticosteroid-induced osteoporosis, Rheumatology, 2002, 41, 1088-1094.
34. Doherty WJ, Derome ME, Mc Carthy MB, Gronowicz GA, Connecticut F, The effect of glucocorticoids on osteoblast function, The Journal of Bone and Joint Surgery, 1995, 77, 396-404.
35. Mazziotti G, Giustina A, Canalis E, Bilezikian JP, Glucocorticoid-Induced Osteoporosis: Clinical and Therapeutic Aspects, Arquivos Brasileiros de Endocrinologia & Metabologia, 2007, 51, 1404-1412.
36. Rubin MR, Bilezikian JP, New anabolic therapies in osteoporosis. Endocrinology Metabolisms Clinics of North America, 2003, 32, 285-307.
37. Kuttikat A, Grant R, Chakravarty K, Management of osteoporosis, Journal of Indian Rheumatology Association, 2004, 12, 1-12.
38. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate or both in men with osteoporosis. New England Journal of Medicine, 2003;349:1216-1226.
39. Ahmed I, Kumar L, Kumar V, Kulkarni KS, Efficacy of OST-6, a polyherbal formulation in the management of osteoporosis in postmenopausal women, Orthopaedics Today, 2002, 4, 241-244.